• Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line).
  

PubMed=15520187; DOI=10.1158/0008-5472.CAN-04-0826
Nicholson B.E., Frierson H.F. Jr., Conaway M.R., Seraj J.M., Harding M.A., Hampton G.M., Theodorescu D.
Profiling the evolution of human metastatic bladder cancer.
Cancer Res. 64:7813-7821(2004)

PubMed=19147813; DOI=10.2353/ajpath.2009.080538; PMCID=PMC2630547
Smith S.C., Nicholson B., Nitz M.D., Frierson H.F. Jr., Smolkin M., Hampton G.M., El-Rifai W., Theodorescu D.
Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination.
Am. J. Pathol. 174:371-379(2009)

PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)